1,026 results on '"Masi, Gianluca"'
Search Results
152. Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer
153. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status
154. Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy
155. Rectal Resection and Knight-Griffen pelvic anastomosis in cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for peritoneal carcinosis: Should fecal diversion be a routine procedure?
156. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature
157. Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.
158. Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study.
159. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC): an option for patients (pts) with uncommon histologies (UH)?
160. Upfront FOLFOXIRI Plus Bevacizumab with or Without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (ATEZOTRIBE): A Multicentre, Open-Label, Phase 2, Randomised Controlled Trial by GONO
161. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
162. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
163. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
164. La scienza del cosmo vive tempi straordinari.
165. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
166. Superhumps in Cataclysmic Binaries. XXIV. Twenty More Dwarf Novae
167. The 2001 Superoutburst of WZ Sagittae
168. 360 Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
169. Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study
170. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study
171. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications
172. OPINION: First-line chemotherapy for mCRC—a review and evidence-based algorithm
173. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers
174. Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database
175. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer
176. Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study
177. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
178. In Reply
179. Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?
180. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
181. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
182. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
183. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib
184. Angiopoietin-2 early increase to predict benefit from regorafenib in metastatic colorectal cancer (mCRC) patients: The prospective REGOLAND study.
185. Chemotherapy intensification
186. Overview on the development of the DEMO diagnostic and control system
187. The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis
188. Assessment of Measurement Performance for a Low Field Side IDTT Plasma Position Reflectometry System
189. THU-134 - Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction
190. THU-145 - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
191. THU-143 - Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients
192. THU-131 - Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib
193. THU-116 - The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab
194. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation
195. Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer
196. Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
197. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis
198. Treatment and Survival Outcomes by Age Following Second-Line Therapy for Metastatic CRC (mCRC): Analysis of 13,149 Patients from the ARCAD Clinical Trials Program
199. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
200. Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.